Givlaari, Nubeqa among Jan CHMP decisions
The committee recommended fifteen medicines for approval at its first meeting of 2020, as well as six extensions of current indications.
Read More
Tag: recommendations
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
